Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693843 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
A Phase 2 study of Obesity, Overweight, or Chronic Weight Management, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
- 20
- Study locations
NCT06693843 is a Phase 2 study of Obesity, Overweight, or Chronic Weight Management that is active but no longer recruiting, run by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. The registered enrollment target is 220 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT06693843, a Phase 2 study of Obesity, Overweight, or Chronic Weight Management, is active but no longer recruiting, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at least one weight-related comorbidity. Participants will be randomized to aleniglipron or placebo in a ratio of 3:1 within each Cohort receiving multiple-ascending, QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 36 weeks of treatment. At the end of the study (after completing 36 weeks of treatment), participants will be offered to continue with an open-label extension (OLE) where they will receive aleniglipron for an additional 36 weeks.
Conditions Studied
Interventions
- DRUG Aleniglipron
- DRUG Aleniglipron or Placebo
Study Locations (20)
California
- ACCESS Research Site - Anaheim
- ACCESS Research Site - Los Angeles
- ACCESS Research Site - Montclair
- ACCESS Research Site - Rancho Cucamonga
- ACCESS Research Site - Sacramento
- ACCESS Research Site - Spring Valley
Illinois
- ACCESS Research Site - Chicago
- ACCESS Research Site - Chicago
- ACCESS Research Site - Evanston
Missouri
- ACCESS Research Site - City of Saint Peters
- ACCESS Research Site - Hazelwood
- ACCESS Research Site - Springfield
Indiana
- ACCESS Research Site - Muncie
- ACCESS Research Site - Valparaiso
Arizona
- ACCESS Research Site - Phoenix
Hawaii
- ACCESS Research Site - Honolulu
Iowa
- ACCESS Research Site - West Des Moines
Louisiana
- ACCESS Research Site - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2024-10-17 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06693843
The ClinicalTrials.gov registry entry for NCT06693843 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity, Overweight, or Chronic Weight Management appearing as the primary indexed condition, and to 2 interventions - of which Aleniglipron is the first listed.
NCT06693843 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Illinois, Missouri.
Frequently Asked Questions
What is clinical trial NCT06693843 about?
NCT06693843 is a clinical study titled "A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity". This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at least one weight-related comorbidity. Participants will be randomized t...
What is the current status of trial NCT06693843?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2024-10-17. Estimated completion is 2026-08.
What conditions does trial NCT06693843 study?
This clinical trial studies the following conditions: Obesity, Overweight, or Chronic Weight Management.
What interventions are being tested in trial NCT06693843?
The interventions under investigation include: Aleniglipron (DRUG), Aleniglipron or Placebo (DRUG).
Who is sponsoring clinical trial NCT06693843?
This trial is sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693843 being conducted?
This trial has 20 study locations across Arizona, California, Hawaii, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity, Overweight, or Chronic Weight Management
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.